Drug Sponsors

EMD Serono to open $115M life science campus in Massachusetts

Tuesday, July 19, 2016

EMD Serono, known as Merck outside of the U.S. and Canada, a science and technology company, has announced plans to build a new campus in Burlington, Massachusetts, that will serve as a major hub for the North American life science business of Merck. The 280,000-square-foot facility will include a customer collaboration laboratory and training center as well as office space.

[Read More]

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals

Tuesday, July 5, 2016

Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant Pharmaceuticals, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The acquisition gives Bristol-Myers Squibb full rights to Cormorant’s HuMax-IL8 antibody program and the lead candidate HuMax-IL8, a phase I/II monoclonal antibody targeted against interleukin-8 (IL-8) that represents a potentially complementary immuno-oncology mechanism of action to T-cell directed antibodies and co-stimulatory molecules.

[Read More]

Biogen selects Cognizant’s SmartTrials Platform

Friday, July 1, 2016

Biogen has selected Cognizant‘s SmartTrials platform to aggregate and store clinical trial operational and patient data. Cambridge, Mass.-based Biogen has a portfolio of medicines to treat multiple sclerosis (MS) and is at the forefront of neurology research, working to develop novel therapies for conditions with few or no treatment options.

[Read More]

Richter acquires Finox Holding for $185.2M

Friday, July 1, 2016

Gedeon Richter has announced the acquisition of Finox Holding, a privately held Swiss biotech company focused on development and commercialization of innovative and cost effective products addressing female fertility. Gedeon Richter, headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. 

[Read More]

CenterWatch joins WIRB-Copernicus Group

Wednesday, June 22, 2016

WIRB-Copernicus Group (WCG), one of the world’s leading providers of solutions that measurably improve the quality and efficiency of clinical research, today announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information, and the addition of Kenneth A. Getz, CenterWatch founder and owner, to its board of directors.

[Read More]